Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo‐controlled, clinical trial

Authors:

Abstract
: Purpose:  To assess the effect of triamcinolone acetonide over 3 months on hard exudates in patients with diabetic macular oedema (DMO).Methods:  Thirty‐two eyes of 16 patients with DMO and hard exudates were included in a randomized, placebo‐controlled trial. Treated eyes received a single‐dose (4 mg) intravitreal injection of triamcinolone acetonide. Control eyes received an injection of subconjunctival saline.Results:  The overall area of hard exudates decreased significantly between the baseline and 3‐month visits in treated eyes, but not in control eyes. The mean change in level of hard exudates between the two visits was − 0.75 arbitrary units (AU) (95% confidence interval [CI] − 1.32 to − 0.18) in the central plus inner circle (1500 μm) and − 0.81 AU (95% CI − 1.49 to − 0.13) over the whole grid (3000 μm) in treated eyes, compared with 0.31 AU (95% CI − 0.19 to 0.82) and 0.31 AU (95% CI − 0.11 to 0.74), respectively, in control eyes (p < 0.001). Mean visual acuity improved by five letters in treated but not in control eyes (p = 0.01).Conclusions:  Intravitreal triamcinolone reduces hard exudates in the short‐term in eyes with DMO.

This publication has 28 references indexed in Scilit: